Gestational%20diabetes%20mellitus Signs and Symptoms

Signs and Symptoms

Introduction

Gestational Diabetes Mellitus (GDM)

Any degree of glucose intolerance with onset or first recognition during pregnancy
- It is diabetes that is first diagnosed in the 2nd or 3rd trimester of pregnancy that has not been a pre-existing type 1 or 2 diabetes
Hyperglycemia in pregnancy may be suggested by the presence of glycosuria, a fetus that is large for date, or polyhydramnios
Prevalence of GDM appears to be high in South Asia and South East Asian women compared to African-American, Caucasian and Hispanic women; prevalence rates are 3-21.2% in women with GDM who were born in Asian countries
- Rates of fetal macrosomia are lower in South East Asian women than in American Caucasian women
- Asian women with GDM have a higher incidence of abnormal postpartum glucose tolerance tests and risk of developing type 2 DM in the future is higher than in Anglo-European women

Early and consistent: Breakthrough results in HFpEF similar to HFrEF

14 Jan 2022

HFpEF represents a significant unmet need in CV medicine due to its prevalence, poor prognosis, and the absence of clinically proven therapeutic options. The EMPEROR-Preserved trial demonstrated the continuous clinical benefits in cardiorenal outcomes of empagliflozin in adults with HFpEF, which were consistent with the observations in adults with HFmrEF/ HFpEF in the EMPEROR-reduced trial. The combined results of the EMPEROR trials establish empagliflozin’s efficacy in heart failure regardless of ejection fraction – and if approved, empagliflozin would become the first and only clinically proven therapy to improve outcomes for the full spectrum of the disease. Therefore, empagliflozin offers a new hope for people living with heart failure.

Dapagliflozin DELIVERs across full HF spectrum regardless of LVEF

Elvira Manzano, 04 Oct 2022

The selective, oral sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF or HFpEF) in the phase III DELIVER* trial, touted as the largest and most inclusive thus far in this patient group.

Product Highlight - QTERN

29 Nov 2019

Saxagliptin 5 mg, dapagliflozin 10 mg FC tab